The Lynx Group

Cost Is Crucial When Evaluating Treatment



Linda D. Bosserman, MD, FACP
Clinical Assistant Professor
Medical Oncology and Hematology
City of Hope Medical Group
Rancho Cucamonga, CA

In today’s environment, there is no way the oncologist can avoid understanding the cost and the outcome issue if we’re going to help our patients evaluate what the regimens we’re recommending or the total treatment course; toxicity, short- and long-term, outcome; and what their cost is going to be.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: